Overview

Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients

Status:
Suspended

Trial end date:
2022-01-01

Target enrollment:
0

Participant gender:
All

Summary

This study aims to study the effects that two standard of care immunosuppression induction regimens have on regulatory T cells (Treg) in live donor renal transplant recipients. Both regimens are currently used in this hospital for early immunosuppression induction but the effects on Treg numbers and function is not well understood and likely will impact long term immune function.

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Pennsylvania

Treatments:

Antibodies, Monoclonal
Antilymphocyte Serum
Basiliximab
Thymoglobulin

Criteria

Inclusion Criteria:

- adult patients receiving first live donor kidney transplant. 0-10% panel reactive
antibody

Exclusion Criteria:

- HIV positive, hepatitis C positive, pregnancy, inability to provide informed consent